By Fineline Cube Germany-based Boehringer Ingelheim and its US partner Eli Lilly & Co., (NYSE: LLY), have reported receiving European Commission (EC) approval for Jardiance (empagliflozin) as a treatment for adults with chronic kidney disease (CKD). This marks an expansion of Jardiance’s indications, which already include type 2 diabetes and heart failure.
Expanding Access to Jardiance in Europe
The approval opens up the use of Jardiance, an SGLT-2 inhibitor, to a significant CKD patient population in Europe, estimated at around 47 million people. The filing was supported by data from the EMPA-KIDNEY trial, which demonstrated a significant benefit of empagliflozin in reducing the relative risk of kidney disease progression or cardiovascular death by 28 percent compared to placebo in individuals with chronic kidney disease (HR; 0.72; 95% CI 0.64 to 0.82; P<0.000001 [absolute risk reduction 3.8%]).
History of Alliance and Global Reach
Boehringer Ingelheim and Lilly first formed an alliance in 2011, focusing on the promotion of several diabetes drugs. This alliance is global in scope, with the two companies deciding on co-promotion or separate promotion territories based on their respective strengths in each market. The approval of Jardiance for CKD further strengthens the partnership and broadens the impact of their collaborative efforts in addressing significant health challenges.-Fineline Info & Tech